American Renal Associates Holdings, Inc. (NYSE:ARA) is now up 17.88% compared to a 12-month low of $5.48. We have seen the price to move -5.14% lower and get settled at $6.46 on 6/5/2019. At recent session, it appeared stuck in a range of $6.55 to $6.93. This company shares are 33.13% off its target price of $8.6 and the current market capitalization stands at $211.76M. The recent change has given its price a -4.08% deficit over SMA 50 and -73.07% deficit over its 52-week high. The stock witnessed -16.43% declines, -49.73% declines and -61.06% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARA’s volatility during a week at 5.99% and during a month it has been found around 6.04%.American Renal Associates Holdings, Inc. (ARA) Top Holders
Institutional investors currently hold around $199 million or 93.4% in ARA stock. Look at its top three institutional owners: Centerbridge Partners, L.P. owns $119.96 million in American Renal Associates Holdings, Inc., which represents roughly 56.65% of the company’s market cap and approximately 60.28% of the institutional ownership. Similar statistics are true for the second largest owner, Van Berkom & Associates Inc., which owns 2,689,168 shares of the stock are valued at $18.31 million. The third largest holder is Vanguard Group Inc, which currently holds $9.63 million worth of this stock and that ownership represents nearly 4.55% of its market capitalization.
At the end of March reporting period, 25 institutional holders increased their position in American Renal Associates Holdings, Inc. (NYSE:ARA) by some 689,752 shares, 50 decreased positions by 2,480,407 and 13 held positions by 26,034,863. That puts total institutional holdings at 29,205,022 shares, according to SEC filings. The stock grabbed 7 new institutional investments totaling 88,980 shares while 21 institutional investors sold out their entire positions totaling 987,979 shares.American Renal Associates Holdings, Inc. (NYSE:ARA) Insider Trades
Multiple company employees have indulged in significant insider trading. American Renal Associates Holdings, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that VP, GC AND SECRETARY Costa Michael Ray has acquired 370 shares of American Renal Associates Holdings, Inc. (ARA) in the trading session dated Apr. 26, 2016. These shares are worth $8,140 and were traded at $22 each. The SEC filing shows that Wilcox Jonathan L performed a purchase of 500 shares. The VP & CFO added these shares by way of transaction on Apr. 26, 2016. The company’s shares were assimilated at $22 per share worth to an investment of some $11,000 to the account of Wilcox Jonathan L.
EVP, COO AND TREASURER, MCDONOUGH JOHN J, purchased 1,000 common shares of American Renal Associates Holdings, Inc. (ARA) in the open market. In a transaction dated Apr. 26, 2016, the shares were bought at an average price of $22, giving away a sum of $22,000. After this purchase, 291,011 common shares of ARA are directly owned by the insider, with total stake valued at $1,879,931.
In the transaction dated Apr. 26, 2016, a great number of shares acquired came courtesy the CEO; Carlucci Joseph A added a total of 500 shares at an average price of $22, amounting to approximately $11,000. The insider now directly owns 654,785 shares worth $4,229,911.
Several analysts have released their opinion on American Renal Associates Holdings, Inc. (NYSE:ARA), with 0 analysts believing it is a strong buy. Whereas 5 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation [T1].